The PRP4 activates p53 and inhibits E-cadherin (Figure 2D,E), suggesting that the specific PRP4–p53 protein interaction induces EMT and resistance to resveratrol and the eventual progression of colon cancer in vivo. This evidence concerns the gene CDH1 and colonic neoplasm.